United Therapeutics Q3 Net Income Falls 24% to $258.6 Million

Bitget2026/11/04 11:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

United Therapeutics’ third-quarter 2026 diluted earnings per share fell 20% year-over-year to $5.71.
Total revenues rose to $832.5 million, while Tyvaso DPI revenues climbed 13% to $378.5 million.
Research and development expense more than doubled to $279.2 million, partly due to acquisition-related research costs for Thymmune.
The board authorized a new $2 billion share repurchase program in October 2026, running through October 21, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611040630BIZWIRE_USPR_____20261104_BW979180) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

United Therapeutics Q3 Net Income Falls 24% to $258.6 Million

You may also like

Crypto prices